Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AB Science partners with Skuldtech for pancreatic cancer companion Dx

This article was originally published in Clinica

Executive Summary

French biopharma firm AB Science and genomic company Skuldtech are developing a companion diagnostic which would identify patients who respond best to masitinib, AB Science's new drug therapy for pancreatic cancer. The test is based on a novel set of biomarkers that were discovered during a Phase III clinical trial evaluating the therapeutic efficacy of a combined masitinib/gemcitabine therapy with the current standard pancreatic cancer treatment of gemcitabine alone.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT099614

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel